SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

NexImmune Management to Present at Upcoming Conferences
[December 02, 2019]

NexImmune Management to Present at Upcoming Conferences


GAITHERSBURG, Md., Dec. 02, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive Officer, will be particpating and presenting a corporate update at the following conferences.  A webcast of Wednesday’s presentation will be available on the Company’s website under the News & Events tab. 

Piper Jaffray’s 31st Annual Healthcare Conference
Tuesday, December 3rd, 3:50PM ET
New York, NY

Evercore’s 2nd Annual HealthCONx Conference
Wednesday, December 4th, 3:50PM ET
Boston, MA

About NexImmune

NexImmune is a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on the proprietary Artificial Immune Modulation (AIM) nanotechnology platform.  The AIM platform enables the ability to expand mlti-antigen specific T cells with enhanced anti-tumor properties without the need for genetic manipulation.  NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer and auto-immune diseases.




The AIM platform is comprised of two core components: (1) a synthetic nanoparticle that functions as an artificial antigen presenting cell (aAPC) to prime and activate T cells directed at multiple tumor antigen targets across a broad range of both solid and hematologic malignancies; and (2) a proprietary T cell enrichment and expansion (E&E) process that controls ex vivo T cell proliferation and subtype differentiation. In preclinical experiments, the AIM system demonstrated the ability to enhance naturally occuring tumor cell recognition, engagement and signaling mechanisms that increased the anti-tumor potency, target specific killing and long-term durability of endogenous cytolytic T-cells.  Utilizing natural target recognition and killing mechanisms may also reduce the potential for alloreactive toxicities observed with genetically engineered T cell therapies.  The Company’s aAPCs have also demonstrated potential utility as both injectable and cellular therapeutic agents.

For more information visit: www.neximmune.com


Contact

Chad Rubin
Solebury Trout
crubin@soleburytrout.com
+1-646-378-2947

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy